Background Vaccination against the most common oncogenic human papillomavirus (HPV)
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …

Background Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will
require a high level of sustained protection against infection and precancerous lesions. Our …

Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …

Background The aim of this interim analysis of a large, international phase III study was to
assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate …

Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous
dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a …

The prevalence of HPV infection in Latin America is among the highest in the world. A
quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has …

We conducted an extended follow-up study (March 2006–May 2008) to assess the longer
term efficacy of a prophylactic monovalent human papillomavirus (HPV) type 16 L1 virus-like …

Background We evaluated the impact of a quadrivalent human papillomavirus (HPV)
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …

Summary Background This Escherichia coli-produced bivalent HPV 16 and 18 vaccine was
well tolerated and effective against HPV 16 and 18 associated high-grade genital lesions …

ContextViruslike particle human papillomavirus (HPV) vaccines were designed to prevent
HPV infection and development of cervical precancers and cancer. Women with oncogenic …